Novel indolodioxanes with antihypertensive effects: potent ligands for the 5-HT1A receptor.

Autor: Ennis MD; Department of Medicinal Chemistry, Upjohn Company, Kalamazoo, Michigan 49001., Baze ME, Smith MW, Lawson CF, McCall RB, Lahti RA, Piercey MF
Jazyk: angličtina
Zdroj: Journal of medicinal chemistry [J Med Chem] 1992 Aug 07; Vol. 35 (16), pp. 3058-66.
DOI: 10.1021/jm00094a021
Abstrakt: The synthesis and biological evaluation of a new family of tricyclic indolodioxanes is described. These compounds all contain the 2,3-dihydro-7H-1,4-dioxino[2,3-e]indole nucleus and bear substituents at the 2 and/or 8 positions. Thirteen members of this class were prepared and shown to be potent ligands for the 5-HT1A receptor, with several compounds displaying subnanomolar inhibition constants. These compounds also bind to the dopamine D-2 receptor, but generally with higher inhibition constants than those for 5-HT1A. Certain members of this novel structural class show in vivo activity in the mouse hypothermia assay. One of these compounds, U-86192A, has been shown to have antihypertensive effects in the cat, completely eliminating sympathetic nerve discharge at 1 mg/kg iv and lowering mean arterial pressure to 50% pretreatment levels. These effects can be reversed by the administration of spiperone, indicating that U-86192A is acting via a central serotonergic mechanism.
Databáze: MEDLINE